AstraZeneca to present next wave of science in respiratory disease at ERS International Congress
65 abstracts to be presented from AstraZeneca’s respiratory portfolio and pipeline including Symbicort in mild to moderate asthma, and Breztri and Fasenra in COPDAstraZeneca will present new data on its portfolio of inhaled combination and biologic therapies, and pipeline of emerging medicines at the European Respiratory Society (ERS) International Congress, which takes place from 28[ ]September to 2 October in Madrid, Spain. The breadth and depth of science is reflected in the 65 abstracts accepted, including 17 oral presentations. In inhaled combinations, a new analysis from the Phase